Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg

American Journal of Psychiatry

Volumn 170, Issue 6, 2013, Pages 642-650

  Zivin, Kara ^a   Pfeiffer, Paul N ^a   Bohnert, Amy S B ^a   Ganoczy, Dara ^a   Blow, Frederic C ^a   Nallamothu, Brahmajee K ^a   Kales, Helen C ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TORSADE DES POINTES; ADULT; AGED; CHEMICALLY INDUCED DISORDER; EVALUATION; FEMALE; HEART DISEASE; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84882252478     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12030408     Document Type: Article

References (37)

1. FDA: FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with High Doses of Celexa (citalopram hydrobromide). Silver Spring, Md, US Food and Drug Administration, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm
2. Moss AJ: Long QT Syndrome. JAMA 2003; 289: 2041-2044
3. US Department of Health and Human Services: FDA Drug Safety Communication: Revised Recommendations for Celexa (citalopram hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses. Silver Spring, Md, US Food and Drug Administration, 2012. http://www.fda.gov/Drugs/ DrugSafety/ucm297391.htm
4. Department of Veterans Affairs Pharmacy Benefits Management: Recommendation for Initial Choice of Selective Serotonin Reuptake Inhibitor (SSRI) in Treatment Naïve Veterans with Major Depression in the Primary Care Setting. Washington, DC, US Department of Veterans Affairs, 2005
5. Blow FC, Valenstein M, McCarthy JF, Visnic S, Miller E, Terlecki S: Specialty Care for Veterans with Depression in the VHA 2009 National Registry for Depression (NARDEP) Report. Ann Arbor, Mich, VA National Serious Mental Illness Treatment Resource and Evaluation Center, Veterans Health Administration Health Services Research and Development, 2011
6. Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC: Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 2004; 161: 654-661
7. Cowper DC, Kubal JD, Maynard C, Hynes DM: A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12: 462-468
8. McCarthy JF, Valenstein M, Kim HM, Ilgen M, Zivin K, Blow FC: Suicide mortality among patients receiving care in the veterans health administration health system. Am J Epidemiol 2009; 169: 1033-1038
9. Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499
10. Hennessy S, Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, Strom BL, Bilker WB: Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19: 555-562
11. Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-1321
12. Weilburg JB, Stafford RS, O'Leary KM, Meigs JB, Finkelstein SN: Costs of antidepressantmedications associated with inadequate treatment. Am J Manag Care 2004; 10: 357-365
13. Quan HD, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139
14. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ: A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009; 47: 626-633
15. Arizona CERT: Drugs with possible risk of torsades de Pointes. http://www.azcert.org/medical-pros/drug-lists/list-02.cfm?sort= Brand-name
16. Arizona CERT: Drugs with risk of torsades de Pointes. http://www.azcert.org/medical-pros/drug-lists/list-01.cfm?sort=Brand- name
17. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics 1995; 51: 524-532
18. McKean AJ, Sola CL, Galardy C, Kung S, Lineberry TW: Reconciling the risk of QT interval prolongation in antidepressants. Pharmacoepidemiol Drug Saf 2012; 21: 329-330, author reply 331-332
19. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S: Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20: 903-913
20. Vieweg WVR, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, Pandurangi AK: Citalopram, QTc interval prolongation, and torsade de pointes: how should we apply the recent FDA ruling? Am J Med 2012; 125: 859-868
21. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S: Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008; 17: 587-592
22. Catalano G, Catalano MC, Epstein MA, Tsambiras PE: QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 2001; 24: 158-162
23. Jimmink A, Caminada K, Hunfeld NGM, Touw DJ: Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 2008; 30: 365-371
24. Rasmussen SL, Overø KF, Tanghøj P: Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19: 407-415
25. Keller MB: Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 2000; 61: 896-908
26. Center for Drug Evaluation and Research. Celexa approval package. Silver Spring, Md, US Food and Drug Administration, 1998
27. Tan JY, Levin GM: Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999; 19: 675-689
28. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220
29. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022
30. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ: Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007; 164: 1198-1205
31. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264-271
32. Howland RH: A critical evaluation of the cardiac toxicity of citalopram: part 2. J Psychosoc Nurs Ment Health Serv 2011; 49: 13-16
33. Howland RH: A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc NursMent Health Serv 2011; 49: 13-16
34. Temple R, Laughren T, Stockbridge N: Removal from labeling of 60-mg citalopram dose. Pharmacoepidemiol Drug Saf 2012; 21: 784-786
35. Lee KC, Feldman MD, Finley PR: Beyond depression: Evaluation of newer indications and off-label uses for SSRIs. Formulary 2002; 37: 312
36. McCarthy JF, Zivin K, Austin KL, Kales HC, Valenstein M: Does consideration of Medicare use affect VA evaluations of treatment for new episodes of depression? Adm Policy Ment Health Ment Health Serv Res 2008; 35: 468-476
37. Lloyd-Jones DM, Larson MG, Beiser A, Levy D: Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89-92